Aardvark Therapeutics, Inc. SEC filings AARD

Aardvark Therapeutics, Inc. has 114 filings in SEC EDGAR's recent list, going back to May 24, 2019. Its latest annual report, Form ARS, was filed on Jul 10, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 11, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 23, 2026 (other events). The company's fiscal year ends on December 31.

Aardvark Therapeutics, Inc. SEC filings
Form Description Filed Period
424B5 Prospectus supplement Apr 3, 2026 —
S-8 Employee stock plan registration Mar 24, 2026 —
S-3 Shelf registration Mar 23, 2026 —
S-8 Employee stock plan registration Aug 13, 2025 —
S-8 Employee stock plan registration Feb 13, 2025 —
424B4 Prospectus Feb 13, 2025 —
S-1/A Amended registration statement Feb 6, 2025 —
S-1 Registration statement Jan 23, 2025 —

Showing 8 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
AARD (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
San Diego, CA
SEC filer status
, Emerging growth company
SEC CIK
1774857

Other Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.